Q2 2026 Scholar Rock Holding Corp Earnings Call Transcript

Aug 6, 2026 / 12:00 PM GMT

Release Date Price: €42.12 (+2.06%)

Transcript 10-Q8-K

Key Points

Positve

Scholar Rock Holding Corp (SRRK) has two independent paths to FDA approval for apitegromab, either through the Catalent, Indiana facility or the second fill-finish facility, providing significant regulatory optionality.
The company has more commercially available vials of apitegromab from its second fill-finish facility than from Catalent, Indiana, and these vials are already at a third-party packaging site, ready for launch upon approval.
Scholar Rock Holding Corp (SRRK) ended Q2 2026 with a strong cash position of $492 million, which includes $63 million in net proceeds from its ATM program, and has access to an additional $150 million debt facility and a priority review voucher to monetize.
The company's commercial organization is fully launch-ready in the US, with preparations including engagement with 140 SMA treatment centers, 2,600 prescribing physicians, and a trained patient services team, positioning it for an immediate launch upon approval.
Scholar Rock Holding Corp (SRRK) is advancing its pipeline beyond SMA, with robust enrollment in the Phase 2 OPAL study for infants, initiation of the Phase 2 FORGE study in FSHD, and promising progress on a subcutaneous formulation and SRK-439, a high-potency myostatin inhibitor.

Negative

The FDA inspection classification for the Catalent, Indiana facility remains pending, which is delayed beyond the typical 90-day guidance period and creates uncertainty for the approval timeline.
European approval of apitegromab is dependent on FDA clearance of the Catalent, Indiana facility, which is currently the sole fill-finish site in the MAA, potentially delaying the European launch.
The company anticipates that most patients prescribed apitegromab will face prior authorization requirements and potential denials, leading to an average time from prescription to infusion of over 60 days during the first six months of launch.
Scholar Rock Holding Corp (SRRK) reported Q2 2026 operating expenses of $108.9 million, including $19.7 million in non-cash stock-based compensation, reflecting increased commercial investments that could pressure future profitability.
The company's reliance on a third-party facility (Catalent, Indiana) for regulatory approval in both the US and Europe exposes it to external operational risks, as evidenced by the ongoing CRL-related issues.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SRRK.OQ - Scholar Rock Holding Corporation
Q2 2026 Scholar Rock Holding Corp Earnings Call
Aug 06, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hi.

Good morning, ladies and gentlemen, and welcome to Scholar Rock's second quarter 2026 conference call.

At this time, all lines are in listen-only mode.

Following the presentation, we will conduct a question-and-answer session.

To ask a question, please press 11 on your telephone, you will then hear an automated message advising that your hand is raised.

If you would like to remove yourself from the queue, press on one again, we also ask that you limit yourself to one question.

This call is being recorded on Thursday, August 6th, 2026.

I would now want to turn the conference over to Scholar Rock, please go ahead.

Good morning, I'm Laura

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.